Treating Alzheimer's and Dementia With D-ribose

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02260141

Enrollment

Registered

2014-10-09

Start date

2014-09-30

Completion date

2017-10-31

Last updated

2020-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimers, Dementia

Brief summary

To study the effectiveness of d-ribose in treating Alzheimer's and Dementia

Detailed description

Clinical experience and the pathophysiology of Alzheimer's, including neuronal insulin resistance, suggests that ribose improves clinical outcomes. This study will add ribose 5 gm 3 X day for 8 weeks to monitor outcomes in a pilot study.

Interventions

DIETARY_SUPPLEMENTd-ribose

giving ribose in those with a diagnosis of Alzheimer's and/or dementia

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

Single arm pilot study using ribose for alzheimers

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* A diagnosis of Alzheimer's and/or dementia with a Mini Mental Status Exam ( MMSE) score over 12 or being ambulatory and able to travel outside the home with assistance. * Must have a caregiver living with them.

Exclusion criteria

* Overt and severe causes of secondary dementia such as metastatic brain cancers, or severe overt infectious encephalopathies or severe autoimmune illness. * Also, severe life threatening illnesses which would make them unlikely to be alive after 6-12 months.

Design outcomes

Primary

Measure	Time frame
ADAS-ADL	2 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026